Association between Levocarnitine Treatment and the Change in Knee Extensor Strength in Patients Undergoing Hemodialysis: A Post-Hoc Analysis of the Osaka Dialysis Complication Study (ODCS)

Nutrients

Tomoaki Morioka¹  Shinya Nakatani¹  Katsuhito Mori²  Tetsuo Shoji³  Yoshihiro Tsujimoto⁴  Masao Yamaguchi⁵  Suhye Lee⁵  Shota Matsufuji⁵  Mari Nishimura⁵  Masanori Emoto⁶ 

[1] Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan;Department of Nephrology, Osaka City University Graduate School of Medicine, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan;Department of Vascular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan;Division of Internal Medicine, Inoue Hospital, Enoki-cho Suita, Osaka 564-0053, Japan;Division of Rehabilitation, Inoue Hospital, Enoki-cho Suita, Osaka 564-0053, Japan;Vascular Science Center for Translational Research, Osaka City University Graduate School of Medicine, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan;

关键词: muscle strength;    hemodialysis;    carnitine deficiency;    sarcopenia;    frailty;   

DOI  :  10.3390/nu14020343

来源: DOAJ

【 摘 要 】

Carnitine deficiency is prevalent in patients undergoing hemodialysis, and it could result in lowered muscle strength. So far, the effect of treatment with levocarnitine on lower limb muscle strength has not been well described. This observational study examined the association between treatment with levocarnitine with the change in knee extensor strength (KES) in hemodialysis patients. Eligible patients were selected from the participants enrolled in a prospective cohort study for whom muscle strength was measured annually. We identified 104 eligible patients for this analysis. During the one-year period between 2014 to 2015, 67 patients were treated with intravenous levocarnitine (1000 mg per shot, thrice weekly), whereas 37 patients were not. The change in KES was significantly higher (p = 0.01) in the carnitine group [0.02 (0.01–0.04) kgf/kg] as compared to the non-carnitine group [−0.02 (−0.04 to 0.01) kgf/kg]. Multivariable-adjusted regression analysis showed the positive association between the change in KES and the treatment with levocarnitine remained significant after adjustment for the baseline KES and other potential confounders. Thus, treatment with intravenous levocarnitine was independently and positively associated with the change in KES among hemodialysis patients. Further clinical trials are needed to provide more solid evidence.

【 授权许可】

Unknown